natgillin/translations-raw huggingface dataset:
Creatinine clearance should be calculated based on actual body weight using the Cockcroft- Gault formula before each Zoledronic acid Teva Pharma dose.
Pred vsakim odmerjanjem zdravila Zoledronska kislina Teva Pharma je treba izračunati očistek kreatinina glede na dejansko maso po Cockcroft-Gaultovi formuli.
Creatinine clearance should be calculated based on actual body weight using the Cockcroft- Gault formula before each Zoledronic acid Teva Pharma dose.
Pred vsakim odmerjanjem zdravila Zoledronska kislina Teva Pharma je treba izračunati očistek kreatinina glede na dejansko telesno maso po Cockcroft-Gaultovi formuli.
Creatinine clearance should be calculated based on actual body weight using the Cockcroft-Gault formula before each zoledronic acid dose.
Pred vsakim odmerjanjem zoledronske kisline je treba izračunati očistek kreatinina glede na dejansko maso po Cockcroft-Gaultovi formuli.
Creatinine clearance should be calculated based on actual body weight using the Cockcroft-Gault formula before each zoledronic acid dose.
Pred vsakim odmerjanjem zoledronske kisline je treba izračunati očistek kreatinina glede na dejansko telesno maso po Cockcroft-Gaultovi formuli.
Creatinine clearance should be calculated based on actual body weight using the Cockcroft-Gault formula before each Zoledronic Acid Hospira dose.
Pred vsakim odmerjanjem zoledronske kisline je treba izračunati očistek kreatinina glede na dejansko telesno maso po Cockcroft-Gaultovi formuli.
Creatinine clearance should be  45 mL/min.
Očistek kreatinina mora biti  45 ml/min.
Creatinine clearance was found to influence the systemic exposure to 5'-DFUR (35% increase in AUC when creatinine clearance decreases by 50%) and to FBAL (114% increase in AUC when creatinine clearance decreases by 50%).
Kreatininski očistek je vplival na sistemsko izpostavljenost 5'-DFUR (35-% povečanje AUC, kreatininski očistek zmanjšan za 50 %) in FBAL (114-% povečanje AUC in padec kreatinskega očistka za 50 %).
Creatinine clearance was found to influence the systemic exposure to 5’-DFUR (35% increase in AUC when creatinine clearance decreases by 50%) and to FBAL (114% increase in AUC when creatinine clearance decreases by 50%).
Kreatininski očistek je vplival na sistemsko izpostavljenost 5´-DFUR (35 % povečanje AUC, kreatininski očistek zmanjšan za 50 %) in FBAL (114 % povečanje AUC in padec kreatinskega očistka za 50 %).
Creatinine clearance was found to influence the systemic exposure to 5’-DFUR (35% increase in AUC when creatinine clearance decreases by 50%) and to FBAL (114% increase in AUC when creatinine clearance decreases by 50%).
Kreatininski očistek je vplival na sistemsko izpostavljenost 5´-DFUR (35-% povečanje AUC, kreatininski očistek zmanjšan za 50 %) in FBAL (114-% povečanje AUC in padec kreatinskega očistka za 50 %).
Creatinine clearance  30 ml/min (monotherapy), serum creatinine  1.5 mg/dl ( 132.6 μmol/l) or creatinine clearance  60 ml/min (combination therapy)
Očistek kreatinina  30 ml/min (monoterapija), kreatinin v serumu  1,5 mg/dl ( 132,6 μ mol/l) ali očistek kreatinina  60 ml/min (kombinirano zdravljenje)
Creatinine clearancea (ml/min)
Očistek kreatininaa (ml/min)
Creatinine elevated
povečane vrednosti kreatinina
Creatinine elevated
povišanje kreatinina
creatinine elevated
zvišan kreatinin
Creatinine elevation
Mukozitis/S tomatitis
Creatinine increased
zvišanje ravni kreatinina
Creatinine increases of >50% from baseline.) and not crude adverse event report frequency.
Zvišanje kreatinina za > 50 % od izhodiščne vrednosti.) in ne groba poročana pogostnost neželenih dogodkov.
Creatinine phosphokinase
kreatinin fosfokinaza
Creatinine renal clearance decreased * Proteinuria # Leukopenia
znižana vrednost ledvičnega očistka kreatinina * proteinurija # levkopenija
Creatinine renal clearance decreasedF, haematocrit increasedE
zmanjšan ledvični očistek kreatininaF, zvišanje hematokritaE
Creatinine value
Vrednost kreatinina
Cresemba
Zdravilo Cresemba
Cresemba 100 mg hard capsules are capsules with a reddish-brown body marked with “100” in black ink and a white cap marked with “C” in black ink.
Cresemba 100 mg so kapsule z rdečkasto-rjavim telesom, na katerem je s črnim črnilom odtisnjena oznaka „100“, ter belim pokrovčkom s črno odtisnjeno oznako „C“.
Cresemba 200 mg is presented in a single use glass vial as a powder for concentrate for solution for infusion.
Zdravilo Cresemba 200 mg je pakirano v stekleni viali za enkratno uporabo v obliki praška za koncentrat za raztopino za infundiranje.
Cresemba is an anti-fungal medicine that contains the active substance isavuconazole.
Zdravilo Cresemba je antimikotik, ki vsebuje zdravilno učinkovino izavukonazol.
CRESEMBA is contraindicated in patients with familial short QT syndrome (see section 4.3).
Zdravilo CRESEMBA je kontraindicirano pri bolnikih z druţinskim sindromom kratkega intervala QT (glejte poglavje 4.3).
CRESEMBA is not recommended for women of childbearing potential who are not using contraception.
Zdravilo CRESEMBA ni priporočljivo za ţenske v rodni dobi, ki ne uporabljajo kontracepcije.
Cresemba is used in adults to treat the following fungal infections: invasive aspergillosis, caused by a fungus in the „Aspergillus‟ group; mucormycosis, caused by a fungus beloning to the „Mucorales‟ group in patients for whom a treatment with amphotericin B is not appropriate.
Zdravilo Cresemba se uporablja pri odraslih za zdravljenje naslednjih glivičnih okuţb: invazivne aspergiloze, ki jo povzroča gliva iz skupine „Aspergillus“; zigomikoze, ki jo povzroča gliva iz skupine „Mucorales“ pri bolnikih, pri katerih zdravljenje z amfotericinom B ni primerno.
Cresemba may make you feel confused, tired or sleepy.
Zaradi zdravila Cresemba se lahko počutite zmedeni, utrujeni ali zaspani.
CRESEMBA must be reconstituted and then further diluted to a concentration corresponding to approximately 0.8 mg/mL isavuconazole prior to administration by intravenous infusion over a minimum of 1 hour to reduce the risk of infusion-related reactions.
Zdravilo CRESEMBA je treba pred uporabo rekonstituirati in nato nadalje razredčiti do koncentracije, ki ustreza pribliţno 0,8 mg/ml izavukonazola; raztopino se da v obliki intravenske infuzije, ki traja najmanj 1 uro, da se zmanjša tveganje infuzijske reakcije.
CRESEMBA must not be used during pregnancy except in patients with severe or potentially life- threatening fungal infections, in whom isavuconazole may be used if the anticipated benefits outweigh the possible risks to the foetus.
Zdravila CRESEMBA se ne sme uporabljati med nosečnostjo, razen pri bolnicah s hudimi ali ţivljenjsko nevarnimi glivičnimi okuţbami, pri katerih je izavukonazol dovoljeno uporabljati, če pričakovane koristi odtehtajo moţna tveganja za plod.
Cresemba treatment will continue for as long as your doctor tells you.
Zdravljenje z zdravilom Cresemba bo trajalo tako dolgo, kot vam predpiše vaš zdravnik.
Cresemba will be given to you by a doctor or nurse.
Zdravilo Cresemba vam bo dal zdravnik ali medicinska sestra.
CRf n (%)
populacijae n = 668
CRh* was defined as  5% of blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets > 50,000/microlitre and ANC > 500/microlitre).
Popolna remisija z delnim hematološkim okrevanjem (CRh*) je bila opredeljena kot  5 % blastov v
cried continuously and could not be comforted for more than 3 hours within 48 hours of vaccination.
neprekinjeno jokal in ga ni bilo mogoče potolažiti več kot 3 ure v 48 urah po cepljenju,
Criteria for a woman of childbearing potential (WCBP)
Merila za ženske v rodni dobi
Criteria for women of non-childbearing potential
Merila za ženske, ki ne morejo zanositi
Critical Instructions for safe and effective use of infusion kit
Pomembna navodila za varno in učinkovito uporabo infuzijskega kompleta
Critical organ bleeding*
Krvavitve v kritične organe
CRIXIVAN - two 200 mg capsules (400 mg) - taken twice a day.
Zdravilo CRIXIVAN - dve 200 mg kapsuli (400 mg) - vzeti dvakrat na dan.
CRIXIVAN 200 mg – packs of 180, 270 and 360 capsules – Bottle label
CRIXIVAN 200 mg – pakiranje po 180, 270 in 360 kapsul – nalepka na plastenki
CRIXIVAN 200 mg – packs of 180, 270 and 360 capsules – Outer carton
CRIXIVAN 200 mg – pakiranje po 180, 270 in 360 kapsul – škatla
CRIXIVAN 400 mg in
CRIXIVAN 400 mg
CRIXIVAN 400 mg – packs of 90 and 180 capsules – Bottle label
CRIXIVAN 400 mg – pakiranje po 90 in 180 kapsul– nalepka na plastenki
CRIXIVAN 400 mg – packs of 90 and 180 capsules – Outer carton
CRIXIVAN 400 mg – pakiranje po 90 in 180 kapsul – škatla
Crixivan can also be taken at a dose of 400 mg twice a day if each dose is taken with 100 mg ritonavir (another antiviral medicine).
Zdravilo Crixivan se lahko jemlje tudi v odmerku 400 mg dvakrat na dan, pri čemer pa je treba ob vsakem odmerku vzeti še 100 mg ritonavirja (drugega protivirusnega zdravila).
Crixivan does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Zdravilo Crixivan ne ozdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter razvoj okužb in bolezni, povezanih z aidsom.
Crixivan has not been
odmerka zdravila Crixivan v
CRIXIVAN helps to: lower the risk that you get illnesses related to HIV lower the amount of HIV in your body (your ‘viral load’) raise your CD4 (T) cell count.
Zdravilo CRIXIVAN pomaga: zmanjšati tveganje za pojav bolezni, povezanih z virusom HIV, zmanjšati količino virusa HIV v telesu ('virusno obremenitev') povečati število CD4 (T) celic.
Crixivan in combination with other antiviral medicines but without ritonavir was more effective than the comparator medicines.
Pri odraslih je bilo zdravilo Crixivan v kombinaciji z drugimi protivirusnimi zdravili, vendar brez ritonavirja, pri zmanjšanju virusnega bremena učinkovitejše od primerjalnih zdravil.
Crixivan is a medicine that contains the active substance indinavir.
Crixivan je zdravilo, ki vsebuje zdravilno učinkovino indinavir.
CRIXIVAN is indicated in combination with antiretroviral nucleoside analogues for the treatment of HIV–1 infected adults.
Zdravilo CRIXIVAN je v kombinaciji s protiretrovirusnimi nukleozidnimi analogi indicirano za zdravljenje z virusom HIV-1 okuženih odraslih.
CRIXIVAN is not recommended in children under the age of 18 years.
Uporaba zdravila CRIXIVAN pri otrocih in mladostnikih do 18. leta starosti ni priporočljiva.
Crixivan is used in combination with other anti-HIV medicines to treat adults infected with human immunodeficiency virus type 1 (HIV 1), a virus that causes acquired immune deficiency syndrome (AIDS).
Zdravilo Crixivan se uporablja v kombinaciji z drugimi zdravili proti okužbi z virusom HIV za zdravljenje odraslih, okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
Crixivan must be used in combination with other antiviral medicines.
Zdravilo Crixivan je treba uporabljati v kombinaciji z drugimi protivirusnimi zdravili.
Crixivan must not be used in patients who are taking any of the following medicines: medicines that are broken down in the same way as Crixivan and are harmful at high levels in the blood;
Prav tako ga ne smejo uporabljati bolniki, ki jemljejo katero od naslednjih zdravil: zdravila, ki se presnavljajo enako kot zdravilo Crixivan in katerih visoke ravni v krvi so škodljive;
Crixivan should not be used in people who may be hypersensitive (allergic) to indinavir or any of the other ingredients.
Zdravila Crixivan ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) indinavir ali katero koli drugo sestavino zdravila.
CRIXIVAN to 400-600 mg
zmanjšanju odmerka zdravila CRIXIVAN na
CRIXIVAN to 600 mg
itrakonazolom se priporoča
CRIXIVAN to 600 mg
zmanjšanju odmerka
CRIXIVAN treats HIV and helps to lower the number of HIV particles in your blood.
Zdravilo CRIXIVAN zdravi okužbo s HIV in pomaga zmanjšati število HIV delcev v vaši krvi.
CRIXIVAN with food and drink
Zdravilo CRIXIVAN skupaj s hrano in pijačo
Crixivan without ritonavir has been studied in three studies involving a total of 524 adults infected with HIV.
Zdravilo Crixivan brez ritonavirja so proučevali v treh študijah, ki so vključevale 524 odraslih, okuženih z virusom HIV.
CRIXIVAN – one 400 mg capsules (400 mg) - taken twice a day.
Zdravilo CRIXIVAN - ena 400 mg kapsula (400 mg) - vzeta dvakrat na dan.
Crixivan, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Zdravilo Crixivan v kombinaciji z drugimi protivirusnimi zdravili zmanjša količino virusa HIV v krvi in ga ohranja na nizki ravni.
Crizotinib has not been studied in patients with hepatic impairment.
Krizotiniba pri bolnikih z okvaro jeter niso preučevali.
Crizotinib is a selective small-molecule inhibitor of the ALK receptor tyrosine kinase (RTK) and its oncogenic variants (i.e.
Krizotinib je selektivni zaviralec tirozinske kinaze receptorja ALK (RTK) in njenih onkogenih različic (t.j.
Crizotinib is also an inhibitor of the Hepatocyte Growth Factor Receptor (HGFR, c-Met) RTK, ROS1 (c-ros) and Recepteur d’Origine Nantais (RON) RTK.
Krizotinib je tudi zaviralec receptorjev rastnega dejavnika hepatocitov (HGFR – Hepatocyte Growth Factor Receptor, c-Met) RTK, ROS1 (c-ros) in receptorjev d’Origine Nantais (RON) RTK.
Crizotinib N=173
krizotinib n = 173
Crizotinib resulted in overall global quality of life benefits with a significantly greater improvement from baseline observed in the crizotinib arm compared to the chemotherapy arm (Cycles 2 to 20; value <0.05).
Krizotinib je povzročil koristne učinke na splošno kakovost življenja, z znatno večjim izboljšanjem od začetka študije v skupini s krizotinibom v primerjavi s skupino s kemoterapijo (cikli od 2 do 20; vrednost p < 0,05).
Crizotinib should not be used in patients with severe hepatic impairment (see sections 4.2, 4.3 and 4.4).
Krizotiniba se ne sme uporabljati pri bolnikih s hudo okvaro jeter (glejte poglavja 4.2, 4.3 in 4.4).
Crizotinib should not be used in patients with severe hepatic impairment (see sections 4.3, 4.4 and 4.8).
Krizotiniba se ne sme uporabljati pri bolnikih s hudo okvaro jeter (glejte poglavja 4.3, 4.4 in 4.8).
Crizotinib significantly prolonged progression-free survival (PFS), the primary objective of the study, compared to chemotherapy as assessed by IRR.
Krizotinib je v primerjavi s kemoterapijo pomembno podaljšal preživetje brez napredovanja bolezni (PFS – Progression-Free Survival), primarni cilj študije, ki se je ocenil s pregledom IRR.
CRM197 protein 16.7-33.3 micrograms
Corynebacterium diphtheriae, 16,7-33,3 mikrograma
CRM197 protein 5.6-10.0 micrograms.
Corynebacterium diphtheriae, 5,6-10,0 mikrograma
CRM197 protein 7.1-12.5 micrograms
Corynebacterium diphtheriae, 7,1-12,5 mikrograma
CRM197, Activated Saccharides, and Conjugates
CRM197, aktivirani saharidi in konjugati
CRNM Bleeding
CRNM krvavitev
Croatia/ Hrvatska
Hrvaška/Hrvatska
Crohn’s disease
Cork Irska
Crohn’s disease
Crohnova bolezen
Crohn’s disease
Crohnove bolezni
Crohn’s disease
Crohnovo bolezen
Crohn’s disease
Linearnost odmerkov
Crohn’s Disease
Psoriatični artritis (PsA)
Crohn’s Disease
Psoriaza s plaki (odrasli bolniki)
Crohn’s disease (6 to 17 years)
Crohnova bolezen (pri bolnikih, starih od 6 do 17 let)
Crohn’s disease (a disease causing inflammation of the digestive tract), when the disease is moderate to severe or fistulising (with the formation of fistulae, abnormal passageways between the gut and other organs);
Crohnovo boleznijo (boleznijo, ki povzroča vnetje prebavnega trakta), ki je zmerna do huda ali fistulirajoča (s fistulami, tj. nenormalnimi prehodi med črevesjem in drugimi organi);
Crohn’s disease (a disease causing inflammation of the digestive tract), when the disease is moderate to severe or fistulising (with the formation of fistulae, abnormal passageways between the gut and other organs);
Crohnovo boleznijo (obolenjem, ki povzroča vnetje prebavnega trakta), kadar je obolenje zmerno do močno izraženo ali pa prihaja do fistulizacije (s pojavljanjem fistul, tj. nenormalnih prehodov med črevesjem in drugimi organi);
Crohn’s disease (a disease causing inflammation of the gut), when the disease is moderate to severe or causes fistulae (abnormal passageways between the gut and other organs);
Crohnove bolezni (bolezni, ki povzroča vnetje črevesja), kadar je bolezen zmerno do močno izražena ali pa prihaja do fistulizacije (nenormalnih prehodov med črevesjem in drugimi organi);
Crohn’s disease and ulcerative colitis
Crohnova bolezen in ulcerozni kolitis
Crohn’s disease clinical trials: in controlled clinical trials, elevations of ALT were similar in patients receiving adalimumab or placebo.
Klinična preskušanja pri Crohnovi bolezni: V kontroliranih kliničnih preskušanjih je bilo zvišanje ALT podobno pri bolnikih, ki so dobivali adalimumab, in pri tistih, ki so dobivali placebo.
Crohn’s disease in adults and children
Crohnova bolezen pri odraslih in otrocih
Crohn’s disease is an inflammatory disease of the bowel.
Crohnova bolezen je vnetna bolezen črevesja.
Crohn’s disease is an inflammatory disease of the bowel.
Primerjava enkratnega in večkratnega odmerjanja
Crohn’s disease is an inflammatory disease of the digestive tract.
Crohnova bolezen je vnetna bolezen prebavil.
Crohn’s disease is an inflammatory disease of the gastrointestinal tract.
Crohnova bolezen je vnetna bolezen prebavil.
Crohn’s disease, ulcerative colitis, and worsening of depression have been associated with COC use.
Z uporabo COC so bili povezani Crohnova bolezen, ulcerozni kolitis in poslabšanje depresije.
Crohn’s disease2
Crohnova bolezen2
Croscarmellose sodium Colloidal hydrated silica Sodium stearyl fumarate Magnesium stearate
premreženi natrijev karmelozat hidratirani koloidni silicijev dioksid natrijev stearilfumarat magnezijev stearat
Croscarmellose sodium, magnesium stearate, microcrystalline cellulose, silicon dioxide.
Premreženi natrijev karmelozat, magnezijev stearat, mikrokristalna celuloza, silicijev dioksid.
Crospovidone
krospovidon,
Crospovidone (E1202) Silica colloidal anhydrous Magnesium stearate (E470b) Lactose monohydrate
Brezvodni koloidni silicijev dioksid Magnezijev stearat (E470b) Laktoza monohidrat
Crospovidone Magnesium stearate
brezvodni koloidni silicijev dioksid povidon krospovidon magnezijev stearat
Crospovidone Magnesium stearate
mikrokristalna celuloza povidon krospovidon magnezijev stearat
Crospovidone Talc
Krospovidon Smukec Aroma svinjine
Cross reactions among thienopyridines
Navzkrižna alergija
Cross reactivity
Kriţne reakcije
Cross resistance between amprenavir and reverse transcriptase inhibitors, is unlikely to occur because the enzyme targets are different.
Malo je verjetno, da bi se med amprenavirjem in zaviralci reverzne transkriptaze pojavila navzkrižna rezistenca, saj so njihovi tarčni encimi različni.
Cross resistance occurs with other macrolides.
Lahko se pojavi navzkrižna rezistenca z drugimi makrolidi.
cross-reactive drug
reakcije, navzkrižna
Cross-reactive immune response against related H5N1 strains
Navzkrižna reaktivnost imunskega odziva proti sevom, sorodnim H5N1
Cross-reactive immune response elicited by A/H5N1/turkey/Turkey/1/05 against A/H5N1/Indonesia/5/05 and A/H5N1/Vietnam/1194/2004
Imunitná odpoveď v rámci skríženej reakcie vyvolaná kmeňom
Cross-reactive immune response elicited by A/H5N1/Vietnam/1194/2004 against A/H5N1/turkey/Turkey/1/05 and A/H5N1/Indonesia/5/05
Imunitná odpoveď v rámci skríženej reakcie vyvolaná kmeňom
Cross-resistance amongst members of the azole class of drugs has been observed within Candida species although resistance to one member of the class does not necessarily confer resistance to other azoles.
Pri zdravilih v azolnem razredu so opazili navzkrižno odpornost proti vrsti Candida, čeprav odpornost proti enemu zdravilu iz tega razreda še ne pomeni odpornosti proti drugim azolom.
Cross-resistance between abacavir and antiretrovirals from other classes (e.g.
Navzkrižna odpornost med abakavirjem in protiretrovirusnimi zdravili iz drugih skupin (npr.
Cross-resistance between tylvalosin and other macrolide antibiotics cannot be excluded.
Navzkrižne rezistence med tilvalozinom in drugimi makrolidnimi antibiotiki ni mogoče izključiti.
Cross-resistance between tylvalosin and other macrolides cannot be excluded.
Navzkrižna rezistenca med tilvalozinom in drugimi makrolidi ni izključena.
Cross-resistance in vitro:
Navzkrižna odpornost in vitro:
Cross-resistance is mainly linked with efflux pumps which confer resistance to β-lactams, quinolones and tetracyclines depending on the specificity of the pump with its substrate.
Navzkrižna rezistenca je večinoma povezana z izlivnimi črpalkami, ki prenašajo odpornost na β- laktame, kinolone in tetracikline, odvisno od specifičnosti črpalke z njenim substratom.
Cross-resistance usually exists between 6–mercaptopurine and 6-thioguanine.
Med 6-merkaptopurinom in 6-tiogvaninom običajno obstaja navzkrižna odpornost.
Cross-resistance within the macrolide group of antibiotics cannot be excluded.
Navzkrižne odpornosti v skupini makrolidnih antibiotikov ni mogoče izključiti.
Cross-resistance within the macrolide group of antibiotics cannot be excluded.
Navzkrižne rezistence v skupini makrolidnih antibiotikov ni mogoče izključiti.
Cross-resistance within the macrolide group of antibiotics cannot be excluded.
Ne moremo izključiti navzkrižne odpornosti znotraj makrolidne skupine antibiotikov.
Cross-resistance: Due to its novel viral target enfuvirtide is equally active in vitro against both wild- type laboratory and clinical isolates and those with resistance to 1, 2 or 3 other classes of antiretrovirals (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors).
Navzkrižna odpornost: zaradi svoje nove virusne tarče je enfuvirtid enako učinkovit in vitro proti divjemu tipu laboratorijskih in kliničnih izolatov in tudi proti tistim z odpornostjo proti 1, 2 ali 3 drugim razredom protiretrovirusnih učinkovin (nukleozidni zaviralci reverzne transkriptaze, nenukleozidni zaviralci reverzne transkriptaze in zaviralci proteaz).
Crossover phase
Faza po navzkrižni zamenjavi zdravila
Crossover to the alternative treatment arm was allowed if patients showed evidence of disease progression or intolerance that could not be managed by dose modification.
Če so se pri bolnikih pokazali znaki napredovanja bolezni ali intolerance, ki jih s prilagoditvijo odmerka ni bilo mogoče nadzirati, jim je bil omogočen prehod v skupino z alternativnim zdravljenjem.
crotal redness, swelling and pain
rdečina, oteklina in bolečina skrotuma
CRPC2 (AFFIRM) study (patients who previously received chemotherapy)
Študija CRPC2 (AFFIRM) (bolniki, ki so predhodno dobivali kemoterapijo)
CRR (CR, CRu), n (%) [95% CI]c p-valuee
CRR (CR, CRu), n (%) [95% IZ]c
Crta. de Susqueda, Amer, 17170 Gerona, Spain
Crta. de Susqueda, Amer, 17170 Gerona, Španija
CRu Rate2 (%)
Nepotrjen popolni odgovor (%)
Cruciate ligament instability: the joint should not possess excessive laxity.
Nestabilna križna vez: sklep ne sme biti pretirano ohlapen.
Crude vaccine effectiveness of one dose of pandemic vaccine among children was 100% (95% CI: 70-100%).
Neobdelana učinkovitost cepiva z enim odmerkom pandemskega cepiva pri otrocih je bila 100 % (95-odstotni interval zaupanja: 70-100 %).
Crush the tablet to a fine powder.
Zdrobite tableto v droben prašek.
Crush the tablet to a powder
Zdrobite tableto v prašek.
Crush the tablets with a pestle and mortar.
Tablete zdrobite s pestilom in možnarjem.
Crushed tablets:
Zdrobljene tablete
crushing chest pain with increased sweating – this may be a serious heart problem (ischaemic heart disease).
tiskajoča bolečina v prsih s povečanim znojenjem – lahko gre za resne težave s srcem (za ishemično bolezen srca);
Crushing, chewing or holding the Enzepi capsules in your or your child’s mouth may cause irritation in your or your child’s mouth or change the way Enzepi works in your or your child’s body.
Drobljenje, žvečenje ali zadrževanje kapsul zdravila Enzepi v vaših ali otrokovih ustih lahko povzroči draženje v ustih ali spremeni način delovanja zdravila Enzepi v telesu.